3 unknown, 1 completed, 1 terminated. 4 Phase 1, 1 Phase 2.
By phase and status
Follow Henlix, Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status
HLX55 - Solid Tumor, Adult | Phase 1 | Unknown | Henlix, Inc | 98 | 2020-03-03 | 2020-05-01 |
Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B Patients
Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibody, Nucleoside/nucleotide analogues - Hepatitis B, Chronic | Phase 2 | Unknown | Henlix, Inc | 44 | 2019-12-31 | 2020-10-20 |
A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors
HLX06 - Solid Tumor, Adult | Phase 1 | Terminated | Henlix, Inc | 5 | 2018-03-22 | 2019-07-30 |
Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors
HLX10 - Solid Tumor | Phase 1 | Unknown | Henlix, Inc | 30 | 2018-02-14 | 2020-06-01 |
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers
HLX07, Acetaminophen, dexamethasone - Solid Tumour | Phase 1 | Completed | Henlix, Inc | 19 | 2016-09-01 | 2019-07-30 |
Conditions studied
Neoplasm Metastasis (3) · Neoplasms (2) · Hepatitis B, Chronic (1)
Interventions
Injections (2) · Acetaminophen (1) · Antibodies, Monoclonal, Humanized (1) · Calcium Dobesilate (1) · Dexamethasone (1) · Diphenhydramine (1) · HLX07 (1) · Nucleosides (1) · Ondansetron (1) · Tenofovir (1) · entecavir (1) · spartalizumab (1)
Countries
Taiwan (5) · United States (1)
Top investigators
Cheng-Yuan Peng, MD, PhD (1) · Chia-Lun Chang, MD (1) · Chia-Yen Dai, MD, PhD (1) · Ching-Liang Ho, MD (1) · Gi-Ming Lai, MD (1) · Jia-Horng Kao, MD, PhD (1) · Tsu-Yi Chao, MD. PhD. (1) · Tus-Yi Chao, MD (1) · Weidong Jiang, Ph.D. (1) · Wu-Chou Su, MD. PhD. (1)
Results publications
PMID 33713216, PMID 38194016